Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.59 |
| ▸ | SCN4A | P35499 | 1/20 | 0.59 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.59 |
| ▸ | BACE1 | P56817 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | MASP2 | O00187 | 1/20 | 0.43 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13655235 | 0.87 | SCN9A (0.62) | SCN9ASCN4ASCN3ABACE1MASP2 | |
| SCHEMBL26304040 | 0.86 | BACE1 (0.50) | SCN9ASCN4ASCN3ABACE1MEN1 | |
| SCHEMBL20501030 | 0.82 | SCN9A (0.61) | SCN9ASCN4ASCN3ASCN5AMASP2 | |
| SCHEMBL28368753 | 0.81 | SCN9A (0.60) | SCN9ASCN4ASCN3ABACE1MEN1 | |
| SCHEMBL20501076 | 0.79 | SCN9A (0.61) | SCN9ASCN4ASCN3AMEN1KMT2A | |
| SCHEMBL20500967 | 0.79 | SCN9A (0.53) | SCN9ASCN4ASCN3ABACE1SCN5A | |
| SCHEMBL13655380 | 0.78 | MAPT (0.57) | SCN9ASCN4ASCN3AMEN1KMT2A | |
| SCHEMBL13655093 | 0.78 | SCN4A (0.58) | SCN9ASCN4ASCN3AMEN1KMT2A | |
| SCHEMBL13655257 | 0.78 | MAPT (0.58) | SCN9ASCN4ASCN3AMEN1KMT2A | |
| SCHEMBL20501157 | 0.78 | SCN9A (0.57) | SCN9ASCN4ASCN3AMASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286922-A1 | ANTIBIOTIC ADJUVANT COMPOUNDS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-09-14 | — | — | US | disclosed |
| US-9975857-B2 | Inhibition of bacterial biofilms with imidazole-phenyl derivatives | NORTH CAROLINA STATE UNIVERSITY (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975857-B2 | Inhibition of bacterial biofilms with imidazole-phenyl derivatives | NORTH CAROLINA STATE UNIVERSITY (US) | 2018-05-22 | — | — | US | disclosed |
| US-20150183746-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | UNIV NORTH CAROLINA STATE (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150183746-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | UNIV NORTH CAROLINA STATE (US) | 2015-07-02 | — | — | US | disclosed |
| US-9005643-B2 | Inhibition of bacterial biofilms with imidazole-phenyl derivatives | NORTH CAROLINA STATE UNIVERSITY (US) | 2015-04-14 | — | — | US | disclosed |
| US-9005643-B2 | Inhibition of bacterial biofilms with imidazole-phenyl derivatives | NORTH CAROLINA STATE UNIVERSITY (US) | 2015-04-14 | — | — | US | disclosed |
| US-20090270475-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270475-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009123753-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286922-A1 | ANTIBIOTIC ADJUVANT COMPOUNDS | MYD88, TLR5, TLR8 | SCN9A 4163/4885SCN4A 4157/4885SCN3A 4376/4885 |
| US-20090270475-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | TFPI, O60361, PGLS | SCN9A 2854/4885SCN4A 4192/4885SCN3A 3773/4885 |
| US-20150183746-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | TFPI, O60361, PGLS | SCN9A 2854/4885SCN4A 4192/4885SCN3A 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.